Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Outcomes of MPN patients versus non-MPN patients hospitalized for COVID-19

Gabriela Hobbs • 11 Dec 2021
ASH 2021
Myeloproliferative Neoplasms

Gabriela Hobbs, MD, Massachusetts General Hospital, Boston, MA, discusses some findings from a retrospective analysis which compared the outcome of myeloproliferative neoplasm (MPN) patients who were hospitalized for COVID-19 versus non-MPN patients who were hospitalized for COVID-19. Dr Hobbs explains that hospitalized patients with MPNs had a higher incidence of thrombotic events compared to non-MPN patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from Gabriela Hobbs

1:20
Future directions in chronic phase CML treatment
Gabriela Hobbs • 11 Dec 2021
1:51
Checkpoint inhibition in the treatment of MPNs
Gabriela Hobbs • 11 Dec 2021
2:07
Antibody and T-cell responses to COVID-19 vaccination in patients with MPNs
Gabriela Hobbs • 11 Dec 2021
2:36
Phase II study of pre-, during-, and post-transplant ruxolitinib for patients with myelofibrosis
Gabriela Hobbs • 11 Dec 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals